Medical management of Crohn's disease: Treatment algorithms 2009

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 536-541

  Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Crohn's disease, goals; Crohn's disease, medical management; Treatment algorithms

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NATALIZUMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG TARGETING; EARLY INTERVENTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION;

EID: 70449505401     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233294     Document Type: Review

References (28)

1. Vermeire S, van Assche G, Rutgeerts P: Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12.
2. Lichtenstein GR, Hanauer SB, Sandborn WJ: Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-484.
3. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al: European evidence- based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55(suppl 1):i16-i35. (Pubitemid 43268291)
4. Hanauer SB: Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis 2009 (in press).
5. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
6. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-362.
7. Hanauer SB: The case for using 5-aminosalicylates in Crohn's disease: pro. Inflamm Bowel Dis 2005; 11: 609-612.
8. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
9. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656.
10. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
11. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled doubleblind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
12. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
13. Van Assche G, Vermeire S, Rutgeerts P: Optimizing treatment of inflammatory bowel diseases with biologic agents. Curr Gastroenterol Rep 2008; 10: 591-596.
14. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al: American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-339.
15. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
16. Sandborn W, Rutgeerts P, Reinisch W, Kornbluth A, Lichtiger S, D'Haens G, et al: Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 2008; 103:S436(A1117).
17. Feagan B, McDonald J, Panaccione R, Enns R, Bernstein CN, Ponich T, et al: A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Late breaking abstract DDW 2008. Gastroenterology 2008; 135: 294-296.
18. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
19. Peyrin-Biroulet L, Colombel JF, Andborn WJ: Insufficient evidence to conclude whether anti-TNF therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol 2009 (in press).
20. Shale M, Kanfer E, Panaccione R, Ghosh S: Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-1641.
21. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-1632.
22. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: the CHARM Trial. Gastroenterology 2007; 132: 52-65.
23. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
24. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
25. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al: Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868.
26. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-1197.
27. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al: Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683. (Pubitemid 46695722)
28. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.